Butyricicoccus pullicaecorum in inflammatory bowel disease.

Venessa Eeckhaut; Kathleen Machiels; Clémentine Perrier; Carlos Romero; Sofie Maes; Bram Flahou; Marjan Steppe; Freddy Haesebrouck; Benedikt Sas; Richard Ducatelle; Severine Vermeire; Filip Van Immerseel

doi:10.1136/gutjnl-2012-303611

Publisher Website

Butyricicoccus pullicaecorum in inflammatory bowel disease.

Authors

Eeckhaut, Venessa
Machiels, Kathleen
Perrier, Clémentine
Romero, Carlos
Maes, Sofie
Flahou, Bram
Steppe, Marjan
Haesebrouck, Freddy
Sas, Benedikt
Ducatelle, Richard
Vermeire, Severine
Van Immerseel, Filip

Type

Published Article

Journal

Gut

Publisher

BMJ

Publication Date

Dec 01, 2013

Volume

62

Issue

12

Pages

1745–1752

Identifiers

DOI: 10.1136/gutjnl-2012-303611

PMID: 23263527

Source

Medline

Keywords

License

Unknown

Abstract

Patients with inflammatory bowel disease have lower numbers of Butyricicoccus bacteria in their stools. Administration of B pullicaecorum attenuates TNBS-induced colitis in rats and supernatant of B pullicaecorum cultures strengthens the epithelial barrier function by increasing the TER.

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. This record was last updated on 07/04/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM. The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/23263527

Report this publication

Statistics

Seen <100 times